alexa Monthly Risedronate for the Treatment of Postmenopausal
ISSN : 2153-2435

Pharmaceutica Analytica Acta
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mini Review

Monthly Risedronate for the Treatment of Postmenopausal Osteoporosis

Jun Iwamoto*

Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan

*Corresponding Author:
Jun Iwamoto
Institute for Integrated Sports Medicine
Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Tel: +81-3-3353-1211
Fax: +81-3-3352-9467
E-mail: [email protected]

Received date: January 20, 2014; Accepted date: Fubruary 24, 2014; Published date: Fubruary 28, 2014

Citation: Iwamoto J (2014) Monthly Risedronate for the Treatment of Postmenopausal Osteoporosis. Pharm Anal Acta 5:285. doi: 10.4172/2153-2435.1000285

Copyright: © 2014 Iwamoto J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Risedronate is a first-line medicine for the treatment of postmenopausal osteoporosis, since meta-analyses of large randomized controlled trials have demonstrated its efficacy against vertebral, nonvertebral, and hip fractures. Risedronate has desirable pharmacological characteristics in terms of its low affinity for bone, and its strong inhibition of farnesyl pyrophosphate synthase rapidly reduces bone turnoverand reverses the effect. Monthly risedronate, which has been recently approved, is non-inferior to daily risedronate in terms of changes in surrogate markers and the incidence of adverse effects. However, the incidence of acute phase reactions is higher for a monthly dosing regimen than for a daily dosing regimen. Because monthly bisphosphonates are superior to weekly bisphosphonates in terms of patient preference and convenience and, consequently, treatment adherence (particularly persistence), monthly risedronate is considered to be useful in clinical practice


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version